Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-01-06

FDA Approved: LINZESS — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Linzess (linaclotide) filed by Allergan, expanding its regulatory status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Linzess (linaclotide)

Snippet

SUPPL AP for LINZESS (LINACLOTIDE)